Most late-stage biopharma deals do not die because of one bad clause. They die because a problem that was visible earlier was never forced into the open. Here’s what that looks like, and why the strategic partner is never one person.
By the time a deal is close to signing, the science, the valuation, the diligence, the regulatory path, the internal approvals, and the personalities have all been tested. If one of those breaks late, it usually means the process was moving faster than the facts, or the wrong people were not aligned early enough.
What many advisors miss is that closing is not only legal execution. It is internal alignment, trust, decision control, and preparation for life after signing.
And the strategic partner is not one person. Advisors often track it as if it were. It is not. It is a group of people with different incentives.
The deal team may be excited, but they do not own the final decision. The business unit may want the asset, but finance does not support the price. R&D may like the science, but commercial does not believe the market. Legal may be fine, but the executive committee has other priorities. A champion may leave, lose influence, or fail to bring the right people along.
When that alignment is missing, it rarely shows up as a “no.” The strategic partner says it is still interested but stops moving. Diligence questions become repetitive. Legal keeps reopening settled points. A new executive appears late. Finance challenges the model. Regulatory, CMC, antitrust, or foreign approval risk is suddenly “too big.” The deal team still likes the asset, but the internal machine has slowed down.
The takeaway: a deal is not real until the real decision-makers are known. The person asking the questions may not be the person who controls budget, strategy, or final approval.
CEOs also need to look inside their own house. Board alignment, the real walk-away position, investor expectations, data-room quality, diligence speed, and consistent messaging can all decide whether a deal survives the final stretch.
And for licenses or partnerships, signing is not the finish line. Governance, decision rights, escalation paths, and alliance management need to be thought through before the contract is signed.
At KYBORA, we help Biopharma leaders close the right strategic transactions globally, by managing the whole closing system: the facts, the people, the approvals, the timing, the handoff into execution, and the trust that holds a deal together.
